Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points

After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations for cardiac failure at long term follow-up. 

ACC 2020 Virtual | COAPT: mejor calidad de vida que se traduce en puntos más duros

Improved quality of life had already been presented, exactly one year ago at the ACC 2019. In that occasion, it was established that the MitraClip reduces symptoms compared against the standard treatment. 

The current analysis was meant to be presented at ACC 2020 together with the World Congress of Cardiology and published simultaneously at J Am Coll Cardiol, and though unfortunately it was impossible to carry out the official presentation due to the COVID19 pandemic, luckily this study’s contributions can reach us via the internet.


Read also: Virtual ACC 2020 | Unlike in TAVR, the Number of Mitral Valve Surgeries Does Not Improve the Outcomes of Transcatheter Mitral Valve Repairs.


The new data indicate that improved quality of life scores will over time translate into prognosis, regardless of the strategy initially employed. That is, improved quality of life would work as a kind of marker of other changes more difficult to quantify, such as anatomy, physiology and hemodynamics. Patients receiving optimal medical treatment (OMT) who saw improved quality of life would also improve at follow-up. 

The original COAPT had showed patients with cardiac failure and severe functional mitral failure had fewer hospitalizations and lower mortality rate (the latter being a secondary endpoint) at 2 years. 

The current analysis focused on 551 patients who survived one month after procedure and completed quality of life forms (279 in the MitraClip group and 272 in the OMT). Patients with MitraClip had better chance of survival, they scored over ten points higher (MitraClip 58% vs OMT 26%).


Read also: Virtual ACC 2020 | Statins Could Also Protect Against Chemotherapy Cardiotoxicity.


For every 10 points in the quality of life score [Kansas City Cardiomyopathy Questionnaire (KCCQ)] there was a 14% reduction of new hospitalization or death risk.

Original title: Health status changes and outcomes in patients with heart failure and mitral regurgitation: from COAPT. 

Reference: Arnold SV et al. J Am Coll Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...